{"generic":"Influenza Virus Vaccine, Live","drugs":["FluMist","FluMist Quadrivalent","Influenza Virus Vaccine, Live"],"mono":{"0":{"id":"jvvvs0","title":"Generic Names","mono":"Influenza Virus Vaccine, Live"},"1":{"id":"jvvvs1","title":"Dosing and Indications","sub":{"0":{"id":"jvvvs1b4","title":"Adult Dosing","mono":"<ul><li>sprayer provides a single dose of 0.2 mL to be administered as 0.1 mL\/nostril<\/li><li><b>Influenza; Prophylaxis:<\/b> (18 to 49 years) one 0.2-mL dose INTRANASALLY (0.1 mL in each nostril) annually<\/li><\/ul>"},"1":{"id":"jvvvs1b5","title":"Pediatric Dosing","mono":"<ul><li>sprayer provides a single dose of 0.2 mL to be administered as 0.1 mL\/nostril<\/li><li><b>Influenza; Prophylaxis:<\/b> (2 to 8 years) one or two 0.2-mL doses INTRANASALLY (0.1 mL in each nostril) annually, based on vaccination history; separate doses by at least a 1-month interval<\/li><li><b>Influenza; Prophylaxis:<\/b> (9 years or older) one 0.2-mL dose INTRANASALLY (0.1 mL in each nostril) annually<\/li><\/ul>"},"3":{"id":"jvvvs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Influenza; Prophylaxis<br\/>"}}},"3":{"id":"jvvvs3","title":"Contraindications\/Warnings","sub":[{"id":"jvvvs3b9","title":"Contraindications","mono":"<ul><li>age less than 2 years or 50 years or older<\/li><li>allergic reaction, severe (eg, anaphylaxis) after previous dose or to vaccine component, including egg protein, gentamicin, gelatin, and arginine<\/li><li>asthma or wheezing in the past 12 months in children aged 2 to 4 years<\/li><li>children and adolescents (2 to 17 years of age) currently receiving aspirin or aspirin-containing therapy; contraindicated due to association of Reye syndrome with aspirin and wild-type influenza infection; avoid use of aspirin within 4 weeks of vaccination unless medically necessary<\/li><li>chronic comorbid conditions; specifically, pulmonary (eg, asthma), cardiovascular (except hypertension), renal, hepatic, neurological, neuromuscular, hematological, or metabolic (eg, diabetes mellitus) disorders<\/li><li>immunosuppression<\/li><li>pregnancy<\/li><\/ul>"},{"id":"jvvvs3b10","title":"Precautions","mono":"<ul><li>acute allergic reaction, including anaphylaxis, has been reported; monitoring and medical management must be available<\/li><li>acute illness with or without fever, moderate to severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>administration of another live vaccine within 4 weeks of live influenza virus vaccine is not recommended<\/li><li>asthma; do not use unless benefit outweighs risk of exacerbation of wheezing; avoid use in severe asthma<\/li><li>concomitant use of antiviral agents against influenza A and\/or B; do not vaccinate within 48 hours of discontinuation of antiviral and do not administer antiviral until 2 weeks after vaccination; if coadministered, consider revaccination<\/li><li>Guillain-Barre syndrome within 6 weeks of a previously administered influenza vaccine; evaluate benefit\/risk before administration<\/li><li>nasal congestion; may interfere with delivery to nasopharyngeal mucosa<\/li><li>underlying medical conditions predisposing patient to complications from wild-type influenza infection; do not administer unless benefit outweighs risk<\/li><li>vaccine recipients in close contact (such as family members) of immunosuppressed person requiring a protected environment (eg, hematopoietic stem cell transplant recipient); risk of transmission to immunocompromised individuals; avoid contact with severely immunocompromised patients for 7 days after vaccination<\/li><li>wheezing, active; do not use<\/li><li>report adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http:\/\/www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jvvvs3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jvvvs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"jvvvs4","title":"Drug Interactions","sub":[{"id":"jvvvs4b13","title":"Contraindicated","mono":"<ul>Aspirin (theoretical)<\/ul>"},{"id":"jvvvs4b14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Peramivir (theoretical)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"},{"id":"jvvvs4b15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Carbamazepine (probable)<\/li><li>Leflunomide (established)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><\/ul>"}]},"5":{"id":"jvvvs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Neurologic:<\/b>Headache (adult, 28% to 40%; pediatric, 3% to 13%)<\/li><li><b>Respiratory:<\/b>Nasal congestion, Nasal discharge, Pain in throat (adult, 19% to 28%; pediatric, 5% to 11%)<\/li><li><b>Other:<\/b>Fever (pediatric, 1% to 9%)<\/li><\/ul>"},"6":{"id":"jvvvs6","title":"Drug Name Info","sub":{"0":{"id":"jvvvs6b17","title":"US Trade Names","mono":"<ul><li>FluMist<\/li><li>FluMist Quadrivalent<\/li><\/ul>"},"2":{"id":"jvvvs6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jvvvs6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jvvvs7","title":"Mechanism Of Action","mono":"Live influenza virus vaccine is available in trivalent (two influenza A strains and one influenza B strain) and quadrivalent (two strains each of influenza A and B) vaccine that provide active immunity against influenza through an incompletely understood mechanism. The vaccine induces the formation of serum antibodies that are specific for strains of the influenza virus.<br\/>"},"9":{"id":"jvvvs9","title":"Administration","mono":"<b>Nasal<\/b><br\/>with vaccine recipient in upright position, insert tip of sprayer just inside the nose and depress plunger rapidly to spray (half the dose); remove dose-divider clip from plunger and administer second half of dose into other nostril <br\/>"},"13":{"id":"jvvvs13","title":"Clinical Teaching","mono":"<ul><li>Warn patient that contact with immunocompromised individuals carries a risk of influenza transmission to those individuals.<\/li><li>Inform patient that there may an an increased risk of wheezing with this vaccine in children younger than 5 years of age who have recurrent wheezing and in persons of any age who have asthma.<\/li><li>Drug may cause runny nose, nasal congestion, and sore throat. This drug may also cause fever (greater than 100 degrees F) in children 2 to 6 years of age.<\/li><li>Advise parent or caregiver that 2 doses of vaccine will need to be administered at least 1 month apart in children 2 to 8 years old who have not previously received influenza vaccination.<\/li><li>Advise parent or caregiver that children and adolescents should avoid taking aspirin and aspirin-containing products until 4 weeks after vaccination, unless medically indicated.<\/li><\/ul>"}}}